In Vitro Toxicology Testing Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product (Bacterial Toxicity Assays, Enzyme Toxicity Assays, Tissue Culture Assays, Western Blots, Cell-Based ELISA, Receptor Binding Assays), By Technology (Cellular Imaging Technology, High Throughput Technology, Toxic Genomics, Cell Culture Technology), By Endpoint (Skin Sensitization and Irritation, Cytotoxicity, Neurotoxicity, Geno Toxicity, Ocular Toxicity, Photo Toxicity, Carcinogenicity, Organ Toxicity, Dermal Toxicity), By Method (Ex Vivo Models, Cellular Assays, Biochemical Assays), By End User (Pharmaceutical Industry, Biopharmaceutical Industry, Cosmetics Industry, Household Products Industry, Chemicals Industry, Food Industry) and Region Forecast 2020-2031

In Vitro Toxicology Testing Market size was valued at US$ 9.9 billion in 2024 and is expected to reach US$ 20.6 billion by 2031, growing at a significant CAGR of 11.0% from 2025-2031. The technique of determining the potential for dangerous compounds is known as in-vitro toxicity testing. It's also utilized to check for the presence of specific hazardous properties in useful substances like agricultural chemicals, therapeutic medications, and food additives. Toxicity testing is required in the development of new compounds since detecting possible toxicity earlier in the drug development process can save time and money, as well as reduce the risk of late-stage failure. In vitro, toxicology testing is used to determine whether hazardous substances or poisons are present in an organism's cells.

In vitro toxicology testing is an analysis of effects of the toxic substances on cultured mammalian cells or bacteria. These techniques are primarily employed for the identification of potentially hazardous chemicals in order to confirm certain toxic properties at the early development stages of therapeutic drugs. The market is highly fragmented due to the presence of many market players, expected to offer lucrative growth during the forecast period. Market players are concentrated on the development of new software solutions, introduction of innovative technologies, enhancing in silico simulation methods in toxicological profiling. Companies are adopting various growth strategies such as new product launches, acquisitions, and mergers in order to enhance the product portfolio and market presence.

Key Developments:

• In February 2025, CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions for accelerated drug discovery and development, launched its PhysioMimix® DILI assay kit: Human 24. This kit, based on CN Bio's human-derived and characterized liver microphysiological system (MPS), offers robust, human-relevant data on key drug safety parameters. The DILI assay kit is designed to support better-informed clinical progression of drug candidates, improve clinical preparedness, and reduce risk in drug development by facilitating the selection of only the most promising therapeutic candidates.
• In February 2025, Creative Bioarray, a leading provider of innovative solutions for biological research and testing, announced the launch of its standard array of in vitro test panels for comprehensive genotoxicity assessment. This suite of services includes key tests recognized by the Organization for Economic Co-operation and Development (OECD) guidelines, positioning Creative Bioarray as a major player in toxicological research.
• In September 2024, Mutagentech and Toxys announced their collaboration on MutaTracker®, a mammalian cell-based assay designed to assess mutagenicity and genotoxicity. MutaTracker® combines the reliable readout of the ToxTracker assay with error-corrected single-molecule mutation sequencing (SMM-seq). ToxTracker is a unique stem cell-based reporter assay used to identify genotoxic potential and provide information about a compound's mode of action (MOA).